Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor-positive Advanced Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06120283
What this trial is testing

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorAdvanced Breast CancerMetastatic Breast Cancer+5 more
BeOne Medicines 433
Testing effectiveness (Phase 2)Study completedNCT02520063
What this trial is testing

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Who this might be right for
Breast Cancer
University of Alabama at Birmingham 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT06105632
What this trial is testing

Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Who this might be right for
Advanced or Metastatic Breast Cancer
Pfizer 333
Not applicableStudy completedNCT03583463
What this trial is testing

ALEXANDRIA Study Egypt

Who this might be right for
Breast Cancer
AstraZeneca 436
Testing effectiveness (Phase 2)Study completedNCT02894398
What this trial is testing

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

Who this might be right for
Breast CancerHormone Receptor Positive TumorHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
iOMEDICO AG 388
Early research (Phase 1)Not Yet RecruitingNCT07590583
What this trial is testing

Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE Trial

Who this might be right for
Advanced Hormone Receptor-Positive Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more
City of Hope Medical Center 20
Testing effectiveness (Phase 2)WithdrawnNCT05234606
What this trial is testing

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Who this might be right for
Urothelial CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer+2 more
Silverback Therapeutics
Testing effectiveness (Phase 2)WithdrawnNCT02115594
What this trial is testing

Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer

Who this might be right for
Breast Cancer
Syndax Pharmaceuticals
Testing effectiveness (Phase 2)Looking for participantsNCT05536128
What this trial is testing

Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor

Who this might be right for
Advanced Breast Cancer
Seoul National University Hospital 64
Early research (Phase 1)Ended earlyNCT05194072
What this trial is testing

Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Who this might be right for
Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms+8 more
Seagen, a wholly owned subsidiary of Pfizer 250
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07658183
What this trial is testing

A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer (Locally Advanced or Metastatic)
Shanghai Best-Link Bioscience, LLC 120
Testing effectiveness (Phase 2)Looking for participantsNCT06832202
What this trial is testing

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

Who this might be right for
HER2-low Hormone Receptor Positive Breast Cancer
Shanghai Henlius Biotech 50
Testing effectiveness (Phase 2)UnknownNCT02630368
What this trial is testing

Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)

Who this might be right for
Solid TumorsSoft-tissue SarcomaBreast Cancer
Institut Bergonié 197
Large-scale testing (Phase 3)Looking for participantsNCT06380751
What this trial is testing

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 788
Testing effectiveness (Phase 2)Study completedNCT03809988
What this trial is testing

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Who this might be right for
Breast CancerAdvanced Breast CancerHormone Receptor Positive Tumor+1 more
MedSIR 198
Large-scale testing (Phase 3)UnknownNCT02404051
What this trial is testing

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CancerHormone Receptor Positive Tumor+2 more
Consorzio Oncotech 745
Testing effectiveness (Phase 2)Ended earlyNCT02269670
What this trial is testing

Phase II Study of Everolimus Beyond Progression

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerProgesterone Receptor-positive Breast Cancer+5 more
Emory University 3
Early research (Phase 1)Study completedNCT02333370
What this trial is testing

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Who this might be right for
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Novartis Pharmaceuticals 88
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Testing effectiveness (Phase 2)Looking for participantsNCT05582499
What this trial is testing

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Who this might be right for
Breast NeoplasmBreast CancerBreast Tumors+7 more
Fudan University 716
Next Page